Syndrome News and Research

RSS

Public and private SARS-CoV-2 T cell receptors may be crucial for pan-coronavirus vaccines

Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.

2 Aug 2021

Oh deer! Antibodies to SARS-CoV-2 detected in 40% of wild white-tailed deer in four U.S. states

Researchers conducting a serosurveillance study of a North American deer species have provided evidence of exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among the animals across four U.S. states.

1 Aug 2021

Antibody responses following SARS-CoV-2 infection more potent than vaccine-elicited ones

Researchers in the United States have conducted a study showing the difference in antibody evolution following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between people who have not previously been infected with the virus and those who have.

1 Aug 2021

Fighting SARS-CoV-2 with nanomedicine

Published in the Journal of Controlled Release, researchers from the German University in Cairo, and the University of Cologne, looked into nano-reformulation of repurposed antiviral and immune-modulating drugs for inhalation therapy against COVID-19. In addition, they focused on how nanomedicine could address the limitations of current therapeutics, enhancing the efficacy, specificity, and safety of such drugs.

1 Aug 2021

Risk of myocarditis from SARS-CoV-2 infection is higher in young males, a study finds

The study highlights that young males with COVID-19 are more susceptible to develop myocarditis than those who received mRNA-based COVID-19 vaccines.

1 Aug 2021

Finding potential microRNAs from humans and plants against SARS-CoV-2

A new study focuses on the identification of probable miRNA candidates from three medicinal plants.

1 Aug 2021

Study looks at potent phytocompounds from Himalayan herbs to treat COVID-19

Considering the antiviral activity of medicinal herbs, a new study published in the journal Current Pharmacology Reports focuses on the identification of potent phytochemicals from Himalayan herbs, namely, Rheum emodi, Thymus serpyllum, and Artemisia annua, for the treatment of COVID-19.

1 Aug 2021

Reactive behavior is a common way to handle unexpected uncertainty, study says

People around the world dramatically changed their shopping behaviors at the start of the COVID-19 pandemic.

31 Jul 2021

Newly identified genetic mutation causes rare, early onset inflammatory bowel disease

Johns Hopkins Medicine researchers, in collaboration with national and international researchers, have identified a genetic mutation in a small number of children with a rare type of inflammatory bowel disease.

30 Jul 2021

Researchers test a library of lipid-based compounds to enable safe delivery of RNA drugs to the lungs

Hokkaido University researchers in Japan created and tested a library of lipid-based compounds to find a way to safely and effectively deliver RNA drugs to the lungs.

30 Jul 2021

BNT162b2 vaccine shows high efficacy at six months

The Pfizer/BioNTech vaccine appears to be highly effective in protecting against the SARS-CoV-2 infection, including its relatively resistant beta variant B.1.351.

30 Jul 2021

Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

A new study reports that the Johnson and Johnson vaccine against COVID-19 shows enhanced efficacy when administered to individuals with pre-existing antibodies.

30 Jul 2021

In-silico prediction of effective drug combinations for the treatment of SARS-CoV-2 infection

A new study published on the bioRxiv preprint server has developed the first computational model, i.e., a signaling network model, that can predict effective repurposed drug combinations to treat different phases of COVID-19 disease. This study has focused on identifying drugs for the treatment of early- and late-stage severe disease.

30 Jul 2021

Scientists suspect Lambda SARS-CoV-2 variant most dangerous

A new study published on the bioRxiv* preprint server used molecular phylogenetic analysis to study the evolutionary trait of the Lambda variant.

30 Jul 2021

SARS-CoV-2 interacts with sialic acid cell surface glycans

In a paper recently uploaded to the journal Frontiers in Chemistry by Li et al. (July 22nd, 2021) the interaction between the SARS-CoV-2 spike protein and N-acetylneuraminic acid (NANA), the most commonly found sialic acid in humans, is investigated, finding that the molecule may act as a secondary or supplementary receptor to the virus.

30 Jul 2021

Phase 1/2 trial results for Nanocovax, protein subunit SARS-CoV-2 vaccine from Vietnam

Nanocovax is a protein subunit vaccine that contains the full-length spike stabilized by the addition of two prolines

29 Jul 2021

Study explains how SARS-CoV-2 variants differ in binding to ACE2 receptor

The current study explored ACE2-RBD interactions with four VoCs including the Alpha, Beta, Gamma, and Delta variants.

29 Jul 2021

Streptococcus pneumoniae modulates host immunity to SARS-CoV-2

Scientists from the UK and US have recently investigated immunological consequences of secondary Streptococcus pneumoniae (S. pneumoniae) infection in coronavirus disease 2019 (COVID-19) patients.

29 Jul 2021

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

Researchers in the United States have provided important insights into the antigen-specific cellular response and evolving humoral (antibody) response to messenger RNA- (mRNA) based vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

29 Jul 2021

Vitamin D supplements are not effective for easing painful IBS symptoms, study reveals

Vitamin D supplements are not an effective treatment for easing painful symptoms of Irritable Bowel Syndrome (IBS), a new study from the University of Sheffield reveals.

29 Jul 2021

Syndrome News and Research

Public and private SARS-CoV-2 T cell receptors may be crucial for pan-coronavirus vaccines

Oh deer! Antibodies to SARS-CoV-2 detected in 40% of wild white-tailed deer in four U.S. states

Antibody responses following SARS-CoV-2 infection more potent than vaccine-elicited ones

Fighting SARS-CoV-2 with nanomedicine

Risk of myocarditis from SARS-CoV-2 infection is higher in young males, a study finds

Finding potential microRNAs from humans and plants against SARS-CoV-2

Study looks at potent phytocompounds from Himalayan herbs to treat COVID-19

Reactive behavior is a common way to handle unexpected uncertainty, study says

Newly identified genetic mutation causes rare, early onset inflammatory bowel disease

Researchers test a library of lipid-based compounds to enable safe delivery of RNA drugs to the lungs

BNT162b2 vaccine shows high efficacy at six months

Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

In-silico prediction of effective drug combinations for the treatment of SARS-CoV-2 infection

Scientists suspect Lambda SARS-CoV-2 variant most dangerous

SARS-CoV-2 interacts with sialic acid cell surface glycans

Phase 1/2 trial results for Nanocovax, protein subunit SARS-CoV-2 vaccine from Vietnam

Study explains how SARS-CoV-2 variants differ in binding to ACE2 receptor

Streptococcus pneumoniae modulates host immunity to SARS-CoV-2

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

Vitamin D supplements are not effective for easing painful IBS symptoms, study reveals

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News